Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Severe rhabdomyolysis associated with the cerivastatin-gemfibrozil combination therapy - Report of a case
Autore:
Lau, TK; Leachman, DR; Lufschanowski, R;
Indirizzi:
Baylor Coll Med, Dept Adult Cardiol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 Adult Cardiol, Houston, TX 77030 USA
Titolo Testata:
TEXAS HEART INSTITUTE JOURNAL
fascicolo: 2, volume: 28, anno: 2001,
pagine: 142 - 145
SICI:
0730-2347(2001)28:2<142:SRAWTC>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
COA REDUCTASE INHIBITOR; COMBINED HYPERLIPIDEMIA; EFFICACY; HYPERCHOLESTEROLEMIA; LOVASTATIN; SAFETY; SIMVASTATIN; MYOPATHY;
Keywords:
anticholesteremic agents; cerivastatin/adverse effects; gemfibrozil/adverse effects; hydroxy-methylglutaryl-CoA reductase inhibitors/adverse effects; hyperlipidemia/drug therapy; rhabdomyolysis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Lau, TK St Lukes Episcopal Hosp, Texas Heart Inst, MC 1-133,6720 Bertner Ave, Houston, TX 77030 USA St Lukes Episcopal Hosp MC 1-133,6720 Bertner AveHouston TX USA 77030
Citazione:
T.K. Lau et al., "Severe rhabdomyolysis associated with the cerivastatin-gemfibrozil combination therapy - Report of a case", TEX HEART I, 28(2), 2001, pp. 142-145

Abstract

Cerivastatin is the new 3rd-generation of the synthetic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, the Ist drugs of choicefor treating hypercholesterolemia. A potent inhibitor of HMG-CoA reductase, it possesses a high affinity for liver tissue and decreases plasma low-density lipoprotein cholesterol at microgram doses. Cerivastatin produces reductions in low-density lipoprotein cholesterol of 31.3% and 36.1 % at dosesof 0.3 and 0.4 mg/day, respectively II is an uncomplicated agent with regard to its pharmacokinetic profile, low potential for interaction with otherdrugs, and suitability for use in those with impaired renal function. Mostother statins have been implicated in causing rhabdomyolysis, either as monotherapy or in combination with other agents. We report what to our knowledge is the most profound case yet in the literature of rhabdomyolysis in association with cerivastatin-gemfibrozil combination therapy, in regard bothto the extreme elevation in serum creatinine kinase and to the patient's near-paralytic weakness.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 02:44:23